Catalyst Wire Dossier Catalyst Wire Dossier

CEM-102 (oral sodium fusidate)

sodium fusidate · Arrevus Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CEM-102 (oral sodium fusidate), covering 2019-04-19 to 2019-04-19. Get the full timeline:

Most recent: Clinical Trial Update: Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections [Phase 3]

See pricing